Rosuvastatin along the cardiovascular continuum: From JUPITER to AURORA

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 11, 2009, Pages 1317-1327

  Barrios, Vivencio ^a   Escobar, Carlos ^a,b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

Author keywords

Cardiovascular continuum; Cardiovascular risk; Cholesterol; LDL cholesterol; Rosuvastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CREATINE KINASE; CYCLOSPORIN; ERYTHROMYCIN; EZETIMIBE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TIROFIBAN; TRIACYLGLYCEROL; WARFARIN;

ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE CONTROL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HEART FAILURE; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; IC 50; KIDNEY FAILURE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; REVIEW; RHABDOMYOLYSIS; SECONDARY PREVENTION; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSIENT ISCHEMIC ATTACK;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; FLUOROBENZENES; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; PRIMARY PREVENTION; PYRIMIDINES; RISK FACTORS; SULFONAMIDES;

EID: 73349137973     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.119     Document Type: Review

References (67)

1. Ergin A, Muntner P, Sherwin R et al. Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States. Am. J. Med. 117, 219-227 (2004).
2. Stamler J, Vaccaro O, Neaton JD et al. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in Multiple Risk Factor Intervention Trial. Diabetes Care 16, 434-444 (1993).
3. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285, 2486-2497 (2001).
4. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227-239 (2004).
5. Kuulasmaa K, Tunstall-Pedoe H, Dobson A et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 355, 675-687 (2000).
6. Menotti A, Kromhout D, Blackburn H et al. Forty-year mortality from cardiovascular diseases and all causes of death in the US Railroad cohort of the Seven Countries Study. Eur. J. Epidemiol. 19, 417-424 (2004).
7. Kotseva K, Wood D, De Backer G et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373, 929-940 (2009).
8. Cannon CP, Steinberg BA, Murphy SA et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J. Am. Coll. Cardiol. 48, 438-445 (2006).
9. Hulten E, Jackson JL, Douglas K et al. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch. Intern. Med. 166, 1814-1821 (2006).
10. Olsson AG, Schwartz GG, Szarek M et al. Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study). Am. J. Cardiol. 99, 632-635 (2007).
11. Wenger NK, Lewis SJ, Herrington DM et al. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann. Intern. Med. 147, 1-9 (2007).
12. Amarenco P, Goldstein LB, Messig M et al. Relative and Cumulative Effects of Lipid and Blood Pressure Control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. Stroke 40(7), 2486-2492 (2009).
13. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J. Clin. Pharmacol. 42, 963-970 (2002).
14. Soran H, Durrington P. Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opin. Pharmacother. 9(12), 2145-2160 (2008).
15. Rader DJ, Davidson MH, Caplan RJ et al. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am. J. Cardiol. 91, C20-C23 (2003).
16. Buckett L, Ballard P, Davidson R et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. Atherosclerosis 151, 41 (2000).
17. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 11, 1160-1164 (2001).
18. McTaggart F, Buckett L, Davidson R et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am. J. Cardiol. 87(Suppl. 5A), B28-B32 (2001).
19. Martin PD, Dane AL, Scheneck et al. Disposition of new HMG CoA reductase inhibitor ZD4522 following dosing in healthy subjects. J. Clin. Pharmacol. 40, 1056 (2000).
20. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br. J. Clin. Pharmacol. 54, 472-477 (2002).
21. Martin PD, Dane AL, Nwose OM et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J. Clin. Pharmacol. 42, 1116-1121 (2002).
22. Jones PH, Davidson MH, Stein EA et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am. J. Cardiol. 92, 152-160 (2003).
23. Schuster H, Barter PJ, Stender S et al. Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am. Heart J. 147, 705-713 (2004).
24. Ballantyne CM, Bertolami M, Hernandez Garcia HR et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY) II. Am. Heart. J. 151, E1-E9 (2006).
25. Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-highdensity lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J. Am. Coll. Cardiol. 52, 626-632 (2008).
26. Leiter LA, Rosenson RS, Stein E et al. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 194, E154-E64 (2007).
27. Fonseca FA, Ruiz A, Cardona-Muñoz EG et al. The DISCOVERY PENTA study: a Direct Statin Comparison of LDL-C Value - an Evaluation of Rosuvastatin Therapy Compared with Atorvastatin. Curr. Med. Res. Opin. 21, 1307-1315 (2005).
28. Faergeman O, Hill L, Windler E et al. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology 111, 219-228 (2008).
29. Clearfield MB, Amerena J, Bassand JP et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia - Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials 7, 35 (2006).
30. Stalenhoef AF, Ballantyne CM, Sarti C et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur. Heart J. 26, 2664-2672 (2005).
31. Ridker PM, Danielson E, Fonseca FA et al. JUPITER study group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
32. Ridker PM, Danielson E, Fonseca FA et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373, 1175-1182 (2009).
33. Glynn RJ, Danielson E, Fonseca FA et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 360, 1851-1861 (2009).
34. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843 (2000).
35. Ridker PM, Rifai N, Rose L et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347, 1557-1565 (2002).
36. Avis HJ, Hutten BA, Gagne C et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia: results from the PLUTO study J. Am. Coll. Cardiol. 53(Suppl. 1), A208 (2009).
37. Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics 122, 198-208 (2008).
38. Wiegman A, Hutten BA, de Groot E et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 292, 331-337 (2004).
39. Rodenburg J, Vissers MN, Wiegman A et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 116, 664-668 (2007).
40. Crouse JR 3rd, Raichlen JS, Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 297, 1344-1353 (2007).
41. Bots ML, Palmer MK, Dogan S et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. J. Intern. Med. 265(6), 698-707 (2009).
42. Underhill HR, Yuan C, Zhao XQ et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am. Heart J. 155, 584, E1-E8 (2008).
43. Miyauchi K, Takaya N, Hirose T et al. Rationale and design of the carotid plaque in human for all evaluations with aggressive rosuvastatin therapy (CHALLENGER trial): evaluation by magnetic resonance imaging. Circ. J. 73, 111-115 (2009).
44. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295, 1556-1565 (2006).
45. Crouse JR III. Thematic review series: patient oriented research; imaging atherosclerosis: state of the art. J. Lipid. Res. 47, 1677-1699 (2006).
46. Rodriguez-Granillo GA, Agostoni P, Garcia-Garcia HM et al. Meta-analysis of the studies assessing temporal changes in coronary plaque volume using intravascular ultrasound. Am. J. Cardiol. 99, 5-10 (2007).
47. Saam T, Ferguson MS, Yarnykh VL et al. Quantitative evaluation of carotid plaque composition by in vivo MRI. Arterioscler. Thromb. Vasc. Biol. 25, 234-239 (2005).
48. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071-1080 (2004).
49. AstraZeneca Pharmaceuticals LP. Crestor (Rosuvastatin Calcium) Prescribing Information. AstraZeneca, Wilmington, DE, USA (2003).
50. Armitage J. The safety of statins in clinical practice. Lancet 370, 1781-1790 (2007).
51. Khush KK, Waters DD, Bittner V et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 115, 576-583 (2007).
52. Raina A, Pickering T, Shimbo D. Statin use in heart failure: a cause for concern? Am. Heart. J. 152, 39-49 (2006).
53. Escobar C, Echarri R, Barrios V. Relative safety profiles of high dose statin regimens. Vasc. Health Risk Manag. 4, 525-533 (2008).
54. Horwich TB, Hamilton MA, Maclellan WR et al. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J. Card. Fail. 8, 216-224 (2002).
55. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J. Am. Coll. Cardiol. 8, 216-224 (2002).
56. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 357, 2248-2261 (2007).
57. Tavazzi L, Maggioni AP, Marchioli R et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 1231-1239 (2008).
58. Pitt B, Loscalzo J, Ycas J et al. Lipid levels after acute coronary syndromes. J. Am. Coll. Cardiol. 51, 1440-1445 (2008).
59. Lablanche JM, Danchin N, Farnier M et al. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/ apolipoprotein A-1 ratio in patients with an acute coronary syndrome: the CENTAURUS trial design. Arch. Cardiovasc. Dis. 101, 399-406 (2008).
60. Di Sciascio G, Patti G, Pasceri V et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J. Am. Coll. Cardiol. 54, 558-565 (2009).
61. Fellström BC, Jardine AG, Schmieder RE et al. AURORA study group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395-1407 (2009).
62. Wanner C, Krane V, März W et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238-248 (2005).
63. Shepherd J, Hunninghake DB, Stein EA et al. Safety of rosuvastatin. Am. J. Cardiol. 94, 882-888 (2004).
64. Kostapanos MS, Milionis HJ, Saougos VG et al. Dose-dependent effect of rosuvastatin treatment on urinary protein excretion. J. Cardiovasc. Pharmacol. Ther. 12, 292-297 (2007).
65. Kostapanos MS, Milionis HJ, Gazi I et al. Rosuvastatin increases α-1 microglobulin urinary excretion in patients with primary dyslipidemia. J. Clin. Pharmacol. 46, 1337-1343 (2006).
66. Vidt DG, Cressman MD, Harris S et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 102, 52-60 (2004).
67. Schuster H. The GALAXY program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev. Cardiovasc. Ther. 5, 177-193 (2007).